Drug Insights

Maximize Your Synapse Use: Your Guide to Searching Atendol

19 March 2024
2 min read

Atendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class. Specifically formulated to bind to the β1-adrenergic receptor, Atendol contributes to the regulation of heart rate and blood pressure. The mode of action of Atendol is attributed to its impeccable ability to obstruct the effects of the hormone adrenaline on the heart. Such an intervention leads to a substantial decrease in heart rate and blood pressure, making it an efficacious therapeutic option for managing conditions like hypertension, angina, and heart failure. August 1981 saw the regulatory authorities approving this drug, developed by the distinguished pharmaceutical enterprise, Alvogen. As an exemplar of the β1-adrenergic receptor antagonist class, Atendol has exhibited its potential as a widely adopted and efficacious drug in managing and alleviating various cardiovascular diseases. Click on the image below to begin the exploration journey of Atendol through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Almirall Secures Exclusive License for ZKN-013 from Eloxx for Rare Skin Disease Treatment
Latest Hotspot
3 min read
Almirall Secures Exclusive License for ZKN-013 from Eloxx for Rare Skin Disease Treatment
19 March 2024
Almirall has entered into an exclusive licensing deal with Eloxx Pharmaceuticals for the use of ZKN-013 in the treatment of uncommon skin conditions.
Read →
Mastering Semaglutide: A Comprehensive Guide to Dosage, Precautions, and Side Effects
Knowledge Base
3 min read
Mastering Semaglutide: A Comprehensive Guide to Dosage, Precautions, and Side Effects
19 March 2024
Semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, is a medication used for weight loss, type 2 diabetes management, and cardiovascular risk reduction.
Read →
BeiGene Wins US Approval for TEVIMBRA® in Post-Chemo Esophageal Cancer
Latest Hotspot
3 min read
BeiGene Wins US Approval for TEVIMBRA® in Post-Chemo Esophageal Cancer
18 March 2024
BeiGene Granted US Regulatory Nod for TEVIMBRA® to Treat Progressive or Spread Esophageal Cancer Post-Chemotherapy.
Read →
Master Morphine Search on Synapse
Drug Insights
2 min read
Master Morphine Search on Synapse
18 March 2024
Morphine Sulfate, an exceptional and potent drug, selectively targets opioid receptors in the body, providing unsurpassed relief from pain and its associated effects.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.